Recurrent Melanoma Recruiting Phase 1 Trials for DB06176 (Romidepsin)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01638533Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionTreatment